Psilocybin and MDMA FDA Approval 2026: What the Fast-Track Decision Means for Depression and PTSD

# Psilocybin and MDMA FDA Approval 2026: What the Fast-Track Decision Means for Depression and PTSD

> **Quick answer:** In April 2026, the FDA fast-tracked review of psilocybin (for treatment-resistant depression and major depressive disorder) and methylone, an MDMA analog (for PTSD), by awarding National Priority Review Vouchers to three companies. These vouchers cut FDA review time from 10-12 months to as little as 1-2 months — but full approval still requires completed Phase 3 trials. Compass Pathways has already reported positive Phase 3 data from two large trials.

The FDA's move to fast-track psilocybin and MDMA-adjacent therapies in April 2026 marks the most significant shift in psychedelic drug policy in over 50 years. For the roughly 30 million Americans living with treatment-resistant depression, and the 13 million with PTSD, this is not a fringe research story — it is potentially the most transformative development in mental health treatment since SSRIs arrived in the late 1980s.

## What the FDA Actually Did — and What It Didn't Do

On April 24, 2026, the FDA awarded National Priority Review Vouchers to three companies developing psychedelic-based treatments under a new Commissioner's National Priority Voucher pilot program. The three recipients are:

- **Compass Pathways** — synthetic psilocybin (COMP360) for treatment-resistant depression - **Usona Institute** — psilocybin (PSIL201) for major depressive disorder - **Transcend Therapeutics** — methylone (TSND-201) for PTSD